phenyl acetate has been researched along with avasimibe in 48 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (18.75) | 18.2507 |
2000's | 28 (58.33) | 29.6817 |
2010's | 11 (22.92) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bousley, RF; Hamelehle, KL; Hicks, JL; Homan, R; Krause, BR; Lee, HT; Picard, JA; Roth, BD; Sliskovic, DR; Speyer, C; Stanfield, RL; Wierenga, W | 1 |
Bousley, RF; Krause, BK; Lee, HT; Ramharack, R; Sekerke, CS; Spahr, MA; Stanfield, RL | 1 |
Krause, BR; Nicolosi, RJ; Wilson, TA | 1 |
Abel, RB; Bullen, WW; Hayes, RN; Lathia, CD | 1 |
Barrett, PH; Huff, MW; Newton, RS; Wilcox, LJ | 1 |
Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Newton, RS; Telford, DE; Wilcox, LJ | 1 |
Bos, MH; de Wit, EC; Havinga, R; Kuipers, F; Post, SM; Princen, HM; Zoeteweij, JP | 1 |
Bocan, TM; Dagle, C; Krause, BR; Lathia, C; Lee, H; Lu, X; Major, T; Mueller, SB; Rosebury, WS | 1 |
Suckling, K | 1 |
Breider, MA; Milad, MA; Robertson, DG | 1 |
de Wit, EC; Delsing, DJ; Gijbels, MJ; Havekes, LM; Jukema, JW; Offerman, EH; Princen, HM; van Der Boom, H; van Der Laarse, A; van Duyvenvoorde, W | 1 |
Auerbach, B; Bak Mueller, S; Bocan, TM; Dagle, C; Krause, BR; Lu, X; Rosebury, WS; Sliskovic, DR | 1 |
Brown, AS; Davidson, MH; Davignon, J; Dujovne, CA; Heinonen, T; Insull, W; Keilson, LM; Koren, M; McLain, R; Schrott, H; Sprecher, D | 1 |
Brown, WV | 1 |
Bennett, AJ; Bennett, J; Higgins, JA; Iddon, CR; Salter, AM; Wilkinson, J | 1 |
Adeli, K; Kulinski, A; Rudy, D; Taghibiglou, C; Van Iderstine, SC | 1 |
Rodriguez, A; Usher, DC | 1 |
Bruckert, E | 1 |
Alegret, M; Díaz, C; Hernández, G; Jové, M; Laguna, JC; Llaverías, G; Sánchez, RM; Vázquez-Carrera, M | 1 |
Anderson, T; Blue, JW; Grégoire, J; Heinonen, T; Imus, J; L'Allier, PL; Lambert, J; Lespérance, J; Rodés, J; Tardif, JC | 1 |
Burnett, JR; Huff, MW | 1 |
Alegret, M; Laguna, JC; Llaverías, G | 1 |
Gilbert, D; Jolley, S; LeCluyse, EL; Milad, MA; Rose, KA; Sahi, J; Stern, RH; Stilgenbauer, L; Wang, H; Zheng, X | 1 |
Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ | 1 |
Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
Gibson, G; Gilbert, D; Jolley, S; LeCluyse, EL; Milad, MA; Rose, KA; Sadagopan, N; Sahi, J; Stern, RH; Stilgenbauer, L; Zheng, X | 1 |
Alfonso, F; Anderson, TJ; Bertrand, O; Blue, J; Grégoire, J; Hassan, A; Heinonen, T; Ibrahim, R; L'Allier, PL; Lespérance, J; McLain, R; Pressler, ML; Reeves, F; Rodés-Cabau, J; Schampaert, E; Tardif, JC; Title, LM | 1 |
Miyazaki, A; Watanabe, T | 1 |
Blue, J; Criqui, MH; Hiatt, WR; Imus, J; Klepack, E; Nehler, M; Regensteiner, JG | 1 |
Barrett, PH; Burnett, JR; Huff, MW; Telford, DE | 1 |
Kanome, T; Miyazaki, A; Watanabe, T | 1 |
Cohen, E; Grégoire, J; Guertin, MC; Heinonen, T; Ibrahim, R; Keller, PF; L'Allier, PL; Lavoie, MA; LeMay, M; Levesque, S; Tardif, JC | 1 |
Berry, C; Grégoire, J; Ibrahim, R; L'Allier, PL; Lespérance, J; Levesque, S; Tardif, JC | 1 |
Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
Barren, C; Berezovska, O; Bhattacharyya, R; Hutter-Paier, B; Huttunen, HJ; Kovacs, DM; Peach, C; Pettingell, W; Windisch, M | 1 |
Bemlih, S; El Andaloussi, A; Poirier, MD | 1 |
Barren, C; Duller, S; Frosch, MP; Havas, D; Hutter-Paier, B; Huttunen, HJ; Kovacs, DM; Peach, C; Windisch, M; Xia, W | 1 |
Charytan, D; Di Carli, MF; Dorbala, S; Ganz, P; McMahon, GT; Schelbert, HR | 1 |
Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F | 1 |
Cheng, JX; Lee, SS; Li, J; Park, K; Ratliff, TL; Tai, JN | 1 |
Bowen, ZD; Bryleva, EY; Chang, CCY; Chang, TY; Harris, BT; Kheirollah, A; Murphy, SR; Niu, Z; Shibuya, Y | 1 |
Bai, Y; Chang, CC; Chang, TY; Chen, S; Li, BL; Li, L; Liu, W; Liu, X; Meng, X; Song, BL; Sun, SC; Wang, J; Wang, L; Xiong, Y; Xu, C; Yan, C; Yang, W; Zhang, J; Zhang, T; Zheng, X; Zhou, P | 1 |
Bandyopadhyay, S; Cheng, JX; Li, J; Oh, ST; Traer, E; Tyner, JW; Zhou, A | 1 |
Chen, X; Song, Q; Xia, L; Xu, X | 1 |
Cai, H; Hu, L; Li, J; Li, YP; Peng, T; Qiu, X; Xia, H; Xiao, J; Yao, W | 1 |
Johnson, B; Lubet, RA; Palen, K; Pan, J; Qiao, L; Sei, S; Shoemaker, RH; Wang, L; Wang, Y; You, M; Zhang, Q | 1 |
9 review(s) available for phenyl acetate and avasimibe
Article | Year |
---|---|
Pharmacological modification of lipoprotein(a).
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Caproates; Cell Line; Cells, Cultured; Humans; Hypolipidemic Agents; Lipoprotein(a); Sulfonamides; Sulfonic Acids | 1999 |
Therapies on the horizon for cholesterol reduction.
Topics: Acetamides; Acetates; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholestyramine Resin; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxysteroid Dehydrogenases; Hypercholesterolemia; Membrane Glycoproteins; Pyrimidines; Rosuvastatin Calcium; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
New advances in lipid-modifying therapies for reducing cardiovascular risk.
Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids | 2002 |
Avasimibe. CI 1011.
Topics: Acetamides; Acetates; Animals; Clinical Trials as Topic; Drug Industry; Humans; Hyperlipidemias; Sulfonamides; Sulfonic Acids | 2002 |
Avasimibe Pfizer.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hyperlipidemias; Sulfonamides; Sulfonic Acids | 2002 |
Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hyperlipidemias; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2003 |
[Acyl-coenzyme A: cholesterol acyltransferase (ACAT)].
Topics: Acetamides; Acetates; Adiponectin; Animals; Arteriosclerosis; Cholesterol Esters; Disease Models, Animal; Drug Design; Foam Cells; Humans; Intercellular Signaling Peptides and Proteins; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids | 2004 |
Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Topics: Acetamides; Acetates; Animals; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Humans; Randomized Controlled Trials as Topic; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Treatment Failure | 2005 |
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia | 2014 |
6 trial(s) available for phenyl acetate and avasimibe
Article | Year |
---|---|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Topics: Acetamides; Acetates; Adult; Aged; Double-Blind Method; Female; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2001 |
Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.
Topics: Acetamides; Acetates; Adult; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypolipidemic Agents; Male; Research Design; Statistics as Topic; Sulfonamides; Sulfonic Acids; Ultrasonography | 2002 |
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2003 |
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Topics: Acetamides; Acetates; Aged; Apolipoproteins B; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Image Processing, Computer-Assisted; Male; Middle Aged; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Failure; Ultrasonography, Interventional | 2004 |
The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease.
Topics: Acetamides; Acetates; Adult; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Exercise; Female; Follow-Up Studies; Humans; Intermittent Claudication; Lower Extremity; Male; Middle Aged; Peripheral Vascular Diseases; Psychomotor Performance; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Time Factors; Treatment Outcome; United States | 2004 |
Coronary circulatory function in patients with the metabolic syndrome.
Topics: Acetamides; Acetates; Adenosine; Adolescent; Adult; Aged; Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cholesterol; Cohort Studies; Coronary Artery Disease; Coronary Circulation; Data Interpretation, Statistical; Double-Blind Method; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Metabolic Syndrome; Middle Aged; Plasminogen Activator Inhibitor 1; Positron-Emission Tomography; Risk Factors; Sulfonamides; Sulfonic Acids; Vascular Resistance; Vasodilator Agents; Young Adult | 2011 |
33 other study(ies) available for phenyl acetate and avasimibe
Article | Year |
---|---|
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Diet; Enzyme Inhibitors; Rabbits; Rats; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 1996 |
CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys.
Topics: Acetamides; Acetates; Animal Feed; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins; Apolipoproteins B; Apoprotein(a); Cells, Cultured; Cholesterol; Enzyme Inhibitors; Lipoprotein(a); Liver; Macaca fascicularis; Male; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 1998 |
The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters.
Topics: Acetamides; Acetates; Animals; Aorta; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cricetinae; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Liver; Male; Reference Values; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Time Factors; Triglycerides | 1998 |
Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay.
Topics: Acetamides; Acetates; Administration, Oral; Animals; Anticholesteremic Agents; Chromatography, High Pressure Liquid; Female; Male; Mass Spectrometry; Rats; Reproducibility of Results; Sulfonamides; Sulfonic Acids | 1998 |
ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB.
Topics: Acetamides; Acetates; Apolipoprotein B-100; Apolipoproteins B; Carbon Radioisotopes; Coenzyme A; Enzyme Inhibitors; Hepatoblastoma; Humans; Hydroxymethylglutaryl CoA Reductases; Intracellular Fluid; Lipid Metabolism; Lipids; Receptors, LDL; RNA, Messenger; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tumor Cells, Cultured | 1999 |
Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Apolipoproteins B; Enzyme Inhibitors; Female; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Swine; Swine, Miniature | 1999 |
Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Bile Acids and Salts; Cells, Cultured; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol Esters; Enzyme Induction; Enzyme Inhibitors; Liver; Male; Rats; Rats, Wistar; RNA, Messenger; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Triglycerides | 1999 |
Avasimibe. CI 1011.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Apolipoproteins B; Cricetinae; Drugs, Investigational; Enzyme Inhibitors; Humans; Liver; Male; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 1999 |
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Base Sequence; Cholesterol; DNA Primers; Enzyme Inhibitors; Gene Expression; Humans; Hypercholesterolemia; Macrophages; Male; Matrix Metalloproteinases; Rabbits; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tissue Inhibitor of Metalloproteinases | 2000 |
Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Topics: Acetamides; Acetates; Administration, Oral; Adrenal Glands; Alanine Transaminase; Animals; Area Under Curve; Arteriosclerosis; Cholesterol; Cytochrome P-450 Enzyme System; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Erythrocytes; Female; Hypolipidemic Agents; Liver; Longevity; Male; Microsomes, Liver; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Toxicity Tests | 2001 |
Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Aortic Valve; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Body Weight; Cell Adhesion; Cell Line; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Eating; Endothelium, Vascular; Female; Heterozygote; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Coenzyme A-Transferases; Drug Therapy, Combination; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Rabbits; Simvastatin; Sulfonamides; Sulfonic Acids | 2001 |
A role for smooth endoplasmic reticulum membrane cholesterol ester in determining the intracellular location and regulation of sterol-regulatory-element-binding protein-2.
Topics: Acetamides; Acetates; Animals; Cholesterol; Cholesterol Esters; Cricetinae; Diet, Atherogenic; DNA-Binding Proteins; Endoplasmic Reticulum, Smooth; Enzyme Inhibitors; Hydroxymethylglutaryl CoA Reductases; Intracellular Membranes; Liver; Mesocricetus; Receptors, LDL; RNA, Messenger; Simvastatin; Sterol O-Acyltransferase; Sterol Regulatory Element Binding Protein 2; Sulfonamides; Sulfonic Acids; Transcription Factors; Triglycerides | 2001 |
Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Topics: Acetamides; Acetates; Apolipoprotein B-100; Apolipoproteins B; Biological Transport; Cysteine Proteinase Inhibitors; Endoplasmic Reticulum; Enzyme Inhibitors; Golgi Apparatus; Humans; Leupeptins; Lipid Metabolism; Oleic Acid; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tumor Cells, Cultured | 2002 |
Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages.
Topics: Acetamides; Acetates; Apolipoproteins E; Cells, Cultured; Cholesterol; Humans; Lipoproteins, LDL; Macrophages; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2002 |
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Topics: Acetamides; Acetates; Atorvastatin; Cells, Cultured; Cholesterol Esters; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Sulfonamides; Sulfonic Acids | 2002 |
Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Topics: Acetamides; Acetates; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Gene Expression; Hepatocytes; Humans; Microsomes, Liver; Midazolam; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Sulfonamides; Sulfonic Acids | 2003 |
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |
Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo.
Topics: Acetamides; Acetates; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Kinetics; Oligonucleotide Array Sequence Analysis; Oxidoreductases, N-Demethylating; Pharmaceutical Preparations; Pregnane X Receptor; Prothrombin Time; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Warfarin | 2004 |
The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Topics: Acetamides; Acetates; Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; Intestine, Small; Kinetics; Lipids; Lipoproteins; Liver; Metabolic Clearance Rate; Models, Biological; Postprandial Period; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Swine; Swine, Miniature; Triglycerides | 2005 |
Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound.
Topics: Acetamides; Acetates; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Male; Middle Aged; Regression Analysis; Sulfonamides; Sulfonic Acids; Total Lung Capacity; Ultrasonography, Interventional | 2006 |
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression.
Topics: Acetamides; Acetates; Aged; Atherosclerosis; Biomarkers; Cineangiography; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Ultrasonography, Interventional | 2007 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.
Topics: Acetamides; Acetates; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; CHO Cells; Cricetinae; Cricetulus; Humans; Mice; Mice, Transgenic; Protein Transport; Pyridines; Secretory Pathway; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2009 |
Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cholesterol Esters; Enzyme Inhibitors; Glioma; Humans; Sulfonamides; Sulfonic Acids | 2010 |
The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.
Topics: Acetamides; Acetates; Aging; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Brain; Cholesterol; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Gliosis; Humans; Image Processing, Computer-Assisted; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Peptide Fragments; Presenilin-1; Pyridines; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2010 |
Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.
Topics: Acetamides; Acetates; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Capsules; Cell Survival; Chemistry, Pharmaceutical; Cholesterol; Esterification; Humans; Male; Mice; Safety; Serum Albumin; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Water | 2015 |
Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Benzimidazoles; Brain; Cells, Cultured; Cholesterol; Cholesterol Esters; Disease Models, Animal; Enzyme Inhibitors; Gene Knockdown Techniques; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Neurons; Peptide Fragments; Presenilin-1; Sulfonamides; Sulfonic Acids; tau Proteins | 2015 |
Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Animals; Atherosclerosis; CD8-Positive T-Lymphocytes; Cell Membrane; Cholesterol; Esterification; Female; Immunological Synapses; Immunotherapy; Male; Melanoma; Mice; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; Signal Transduction; Sulfonamides; Sulfonic Acids | 2016 |
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays | 2017 |
Synergy of Dendritic Cell Vaccines and Avasimibe in Treatment of Head and Neck Cancer in Mice.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Animals; Cancer Vaccines; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Disease Models, Animal; Female; Head and Neck Neoplasms; Immunotherapy; Mice; Mice, Inbred C3H; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Sulfonic Acids; T-Lymphocytes; Vaccines | 2017 |
Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Topics: Acetamides; Acetates; Antiviral Agents; Apolipoproteins B; Apolipoproteins E; Carrier Proteins; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lipid Metabolism; Lipid Regulating Agents; RNA, Small Interfering; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Virion; Virus Assembly | 2017 |
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator.
Topics: Acetamides; Acetates; Amino Acid Sequence; Animals; Cancer Vaccines; Cholesterol; Disease Progression; Lung Neoplasms; Mice; Proto-Oncogene Proteins p21(ras); Sulfonamides; Sulfonic Acids; T-Lymphocytes, Regulatory; Vaccines, Subunit | 2019 |